FDA launches safety study for abortion pill mifepristone, source says

The Food and Drug Administration (FDA) has initiated a safety study of the abortion pill mifepristone, which could lead to restrictions on its access. This retrospective study will examine hundreds of thousands of cases, with interim results expected in July. The study follows a letter from Health and Human Services Secretary Robert F. Kennedy Jr. and former FDA Commissioner Martin Makary, who highlighted the need to review the drug’s safety and efficacy. Mifepristone, approved in 2000, is used with misoprostol to end early pregnancies. The Biden administration had previously lifted restrictions on its distribution, allowing it to be accessed via telehealth and mail. However, legal challenges, such as one from Louisiana, have led to temporary reinstatements of in-person dispensing rules, though the Supreme Court has allowed mail delivery to continue for now. The outcome of the FDA’s review could impact how the drug is prescribed and accessed in the future. QUESTION: How might changes in the availability of mifepristone affect individuals seeking abortions, and what implications could this have for healthcare access?